NATCOPHARMPharmaceuticals
Natco Pharma Ltd — Cash Flow Statement
₹974.20
+0.51%
Natco Pharma Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 1.19K Cr | 852.90 Cr | 643.50 Cr | -196.20 Cr | — |
| Repurchase Of Capital Stock | 0.00 | -253.70 Cr | -7.40 Cr | 0.00 | — |
| Issuance Of Capital Stock | 7.30 Cr | 0.00 | 0.00 | 0.00 | — |
| Capital Expenditure | -511.60 Cr | -358.70 Cr | -205.60 Cr | -242.70 Cr | — |
| End Cash Position | 120.00 Cr | 70.40 Cr | 131.90 Cr | 111.10 Cr | — |
| Beginning Cash Position | 70.40 Cr | 131.90 Cr | 111.10 Cr | 25.80 Cr | — |
| Effect Of Exchange Rate Changes | -22.00 Cr | 6.50 Cr | 11.80 Cr | 9.30 Cr | — |
| Changes In Cash | 71.60 Cr | -68.00 Cr | 9.00 Cr | 76.00 Cr | — |
| Financing Cash Flow | -210.70 Cr | -246.90 Cr | -363.00 Cr | 34.80 Cr | — |
| Interest Paid Cff | -17.60 Cr | -18.10 Cr | -14.20 Cr | -17.00 Cr | — |
| Cash Dividends Paid | -107.80 Cr | -170.80 Cr | -100.40 Cr | -82.20 Cr | — |
| Net Common Stock Issuance | 7.30 Cr | -253.70 Cr | -7.40 Cr | 0.00 | — |
| Common Stock Payments | 0.00 | -253.70 Cr | -7.40 Cr | 0.00 | — |
| Common Stock Issuance | 7.30 Cr | 0.00 | 0.00 | 0.00 | — |
| Net Issuance Payments Of Debt | -89.20 Cr | 197.80 Cr | -239.00 Cr | 138.20 Cr | — |
| Net Short Term Debt Issuance | -89.20 Cr | 197.80 Cr | -239.00 Cr | 138.20 Cr | — |
| Investing Cash Flow | -1.41K Cr | -1.03K Cr | -477.10 Cr | -5.30 Cr | — |
| Net Other Investing Changes | -62.90 Cr | -132.50 Cr | 76.60 Cr | 32.40 Cr | — |
| Interest Received Cfi | 146.60 Cr | 58.50 Cr | 48.80 Cr | 49.80 Cr | — |
| Dividends Received Cfi | 3.30 Cr | 0.30 Cr | 0.10 Cr | 0.20 Cr | — |
| Net Investment Purchase And Sale | -1.10K Cr | -603.50 Cr | -427.50 Cr | 203.90 Cr | — |
| Sale Of Investment | 1.29K Cr | 582.40 Cr | 108.80 Cr | 324.60 Cr | — |
| Purchase Of Investment | -2.40K Cr | -1.19K Cr | -536.30 Cr | -120.70 Cr | — |
| Net Intangibles Purchase And Sale | -90.40 Cr | -19.30 Cr | -59.30 Cr | -9.90 Cr | — |
| Sale Of Intangibles | 20.10 Cr | 0.00 | — | — | 2.30 Cr |
| Purchase Of Intangibles | -110.50 Cr | -19.30 Cr | -59.30 Cr | -9.90 Cr | — |
| Net PPE Purchase And Sale | -306.10 Cr | -337.40 Cr | -115.80 Cr | -179.00 Cr | — |
| Sale Of PPE | 95.00 Cr | 2.00 Cr | 30.50 Cr | 53.80 Cr | — |
| Purchase Of PPE | -401.10 Cr | -339.40 Cr | -146.30 Cr | -232.80 Cr | — |
| Operating Cash Flow | 1.70K Cr | 1.21K Cr | 849.10 Cr | 46.50 Cr | — |
| Taxes Refund Paid | -372.60 Cr | -286.30 Cr | -177.50 Cr | -48.20 Cr | — |
| Change In Working Capital | -199.70 Cr | -309.40 Cr | 62.70 Cr | -231.40 Cr | — |
| Change In Other Current Liabilities | -22.70 Cr | 11.60 Cr | 102.70 Cr | -16.60 Cr | — |
| Change In Other Current Assets | -54.60 Cr | -63.60 Cr | 68.90 Cr | -44.30 Cr | — |
| Change In Payable | 40.30 Cr | -28.10 Cr | 102.00 Cr | 7.40 Cr | — |
| Change In Inventory | -65.30 Cr | 42.40 Cr | 19.10 Cr | 56.40 Cr | — |
| Change In Receivables | -59.30 Cr | -341.30 Cr | -222.10 Cr | -235.20 Cr | — |
| Other Non Cash Items | -163.80 Cr | -82.10 Cr | -38.30 Cr | -22.90 Cr | — |
| Provisionand Write Offof Assets | -2.20 Cr | 22.70 Cr | -23.90 Cr | 27.10 Cr | — |
| Depreciation And Amortization | 235.20 Cr | 186.80 Cr | 163.80 Cr | 142.60 Cr | — |
| Depreciation | 235.20 Cr | 186.80 Cr | 149.30 Cr | 137.80 Cr | — |
| Gain Loss On Investment Securities | -4.70 Cr | 0.40 Cr | 5.10 Cr | -1.40 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -0.80 Cr | -0.80 Cr | 0.00 | -0.90 Cr | — |
| Gain Loss On Sale Of PPE | -90.10 Cr | 1.70 Cr | -17.80 Cr | -42.70 Cr | — |
| Net Income From Continuing Operations | 2.29K Cr | 1.67K Cr | 861.90 Cr | 202.20 Cr | — |
| Common Stock Dividend Paid | — | -170.80 Cr | -100.40 Cr | -82.20 Cr | — |
| Amortization Cash Flow | — | 16.10 Cr | 14.50 Cr | 4.80 Cr | 2.40 Cr |
| Net Business Purchase And Sale | — | — | 0.00 | -103.10 Cr | 0.00 |
| Purchase Of Business | — | — | 0.00 | -103.10 Cr | 0.00 |
| Stock Based Compensation | — | — | 0.00 | 2.20 Cr | 12.60 Cr |
| Net Other Financing Charges | — | — | — | -1.80 Cr | -9.50 Cr |
| Repayment Of Debt | — | — | — | — | -48.40 Cr |
| Short Term Debt Payments | — | — | — | — | -48.40 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Natco Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.